Autologous Ovarian Tissue Transplantation

Description

Chemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO08050491). The objective of this study is to study the efficacy and safety of autologous tissue transplantation in patients diagnosed with primary ovarian insufficiency after chemotherapy and/or radiation treatments.

Conditions

Primary Ovarian Insufficiency, Female Infertility

Study Overview

Study Details

Study overview

Chemotherapy and radiation for cancer and other conditions can cause infertility. Several centers around the world are cryopreserving ovarian tissue from these patients though an experimental protocol, including the Fertility Preservation Program in Pittsburgh (protocol PRO08050491). The objective of this study is to study the efficacy and safety of autologous tissue transplantation in patients diagnosed with primary ovarian insufficiency after chemotherapy and/or radiation treatments.

Autologous Ovarian Tissue Transplantation

Autologous Ovarian Tissue Transplantation

Condition
Primary Ovarian Insufficiency
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States, 15213

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Previously cryopreserved ovarian tissue
  • * Ovarian insufficiency and/or candidate for pregnancy
  • * Good health
  • * Oncologist's clearance
  • * Patients considered to be high risk for surgical complications
  • * Women with contraindication for pregnancy if goal is to achieve pregnancy
  • * Women positive for the BRCA mutations
  • * Women with a history of leukemia, ovarian cancer or a cancer that likely involved ovaries at the time of ovarian tissue collection
  • * Women with psychological, psychiatric, or other conditions which prevent giving fully informed consent
  • * Current pregnancy

Ages Eligible for Study

18 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Pittsburgh,

Kyle Orwig, PhD, PRINCIPAL_INVESTIGATOR, University of Pittsburgh/University of Pittsburgh Medical Center

Study Record Dates

2027-09-01